| Overall (n = 3202) | AP (n = 928) | EU (n = 1113) | LA (n = 90) | US (n = 563) | Japan (n = 508) | |
|---|---|---|---|---|---|---|
| BCLC stage A/B/C/D at initial diagnosisa (% of n) | 22/20/30/3 | 9/16/38/3 | 24/26/32/2 | 23/31/23/8 | 17/12/27/6 | 44/20/18/1 |
| BCLC stage A/B/C/D at start of sorafenib therapya (% of n) | 7/20/52/5 | 3/10/61/5 | 9/24/53/4 | 18/40/29/9 | 10/12/36/12 | 7/32/55/2 |
| Median OS from start of sorafenib therapyb (months) | 10.9 | 9.7 | 11.8 | 13.7 | 8.5 | 14.5 |
| Median TTP from start of sorafenib therapyb (months) | 4.8 | 3.8 | 6.4 | 15.2 | 5.5 | 3.4 |
| Median time from initial diagnosis to start of sorafenib therapy (months) | 3.9 | 2.6 | 3.7 | 1.2 | 2.8 | 24.1 |
| Median time from initial diagnosis to deathb (months): overall | 25.5 | 20.9 | 25.0 | 19.5 | 14.8 | 79.6 |
| BCLC A (n = 686) | 59.2 | 54.0 | 49.3 | 23.3 | 24.9 | 91.0 |
| BCLC B (n = 633) | 29.9 | 31.0 | 27.3 | 22.2 | 19.7 | 47.9 |
| BCLC C (n = 973) | 10.6 | 10.3 | 11.0 | 11.2 | 8.5 | 27.7 |
| BCLC D (n = 91) | 8.9 | 8.9 | 11.0 | NA | 7.5 | 13.1 |
a
Missing/not evaluable patients not tabulated;
b
Based on ITT population (n = 3213; AP = 955, EU = 1115, LA = 90, US = 553, Japan = 500). AP = Asia-Pacific; LA = Latin America; NA = not available